Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34328
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZwickl, Sav-
dc.contributor.authorRuggles, Tomi-
dc.contributor.authorWong, Alex Fq-
dc.contributor.authorGinger, Ariel-
dc.contributor.authorAngus, Lachlan M-
dc.contributor.authorEshin, Kalen-
dc.contributor.authorCook, Teddy-
dc.contributor.authorCheung, Ada S-
dc.date2023-
dc.date.accessioned2023-12-01T02:13:38Z-
dc.date.available2023-12-01T02:13:38Z-
dc.date.issued2024-01-15-
dc.identifier.citationThe Medical Journal of Australia 2024-01-15; 220(1)en_US
dc.identifier.issn1326-5377-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/34328-
dc.description.abstractTo assess rates of disruption of gender-affirming health care, of coronavirus disease 2019 (COVID-19) illness, testing, and vaccination, and of discrimination in health care among Australian trans people during the COVID-19 pandemic. Online cross-sectional survey (1-31 May 2022); respondents were participants recruited by snowball sampling for TRANSform, an Australian longitudinal survey-based trans health study, 1 May - 30 June 2020. People aged 16 years or older, currently living in Australia, and with a gender different to their sex recorded at birth. Proportions of respondents who reported disruptions to gender-affirming health care, COVID-19 illness, testing, and vaccination, and positive and negative experiences during health care. Of 875 people invited, 516 provided valid survey responses (59%). Their median age was 33 years (interquartile range, 26-45 years); 193 identified as women or trans women (37%), 185 as men or trans men (36%), and 138 as non-binary (27%). Of 448 respondents receiving gender-affirming hormone therapy, 230 (49%) reported disruptions to treatment during the pandemic; booked gender-affirming surgery had been cancelled or postponed for 37 of 85 respondents (44%). Trans-related discrimination during health care was reported by a larger proportion of participants than in a pre-pandemic survey (56% v 26%). COVID-19 was reported by 132 respondents (26%), of whom 49 reported health consequences three months or more after the acute illness (37%; estimated Australian rate: 5-10%). Three or more COVID-19 vaccine doses were reported by 448 participants (87%; Australian adult rate: 70%). High rates of COVID-19 vaccination among the trans people we surveyed may reflect the effectiveness of LGBTIQA+ community-controlled organisation vaccination programs and targeted health promotion. Training health care professionals in inclusive services for trans people could improve access to appropriate health care and reduce discrimination.en_US
dc.language.isoeng-
dc.subjectCOVID-19en_US
dc.subjectGender identityen_US
dc.subjectHealthcare disparitiesen_US
dc.subjectVaccinationen_US
dc.titleDisruption of gender-affirming health care, and COVID-19 illness, testing, and vaccination among trans Australians during the pandemic: a cross-sectional survey.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleThe Medical Journal of Australiaen_US
dc.identifier.affiliationThe University of Melbourne, Melbourne, VIC.en_US
dc.identifier.affiliationLa Trobe University, Melbourne, VIC.en_US
dc.identifier.affiliationACON, Sydney, NSW.en_US
dc.identifier.affiliationAustin Healthen_US
dc.identifier.doi10.5694/mja2.52169en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-5257-5525en_US
dc.identifier.pubmedid37994182-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptEndocrinology-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

60
checked on Nov 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.